Intelligent Bio Solutions (NASDAQ:INBS) Announces Quarterly Earnings Results

Intelligent Bio Solutions (NASDAQ:INBS) issued its quarterly earnings data on Wednesday. The company reported ($0.35) EPS for the quarter, Zacks reports. Intelligent Bio Solutions had a negative return on equity of 231.13% and a negative net margin of 346.22%.

Intelligent Bio Solutions Stock Down 4.4%

Shares of NASDAQ INBS traded down $0.04 during midday trading on Wednesday, hitting $0.77. The stock had a trading volume of 187,260 shares, compared to its average volume of 210,318. The stock has a 50 day simple moving average of $1.19 and a 200-day simple moving average of $1.45. The company has a market capitalization of $7.00 million, a PE ratio of -0.38 and a beta of 4.49. Intelligent Bio Solutions has a 1 year low of $0.73 and a 1 year high of $2.75.

Wall Street Analysts Forecast Growth

INBS has been the subject of a number of recent analyst reports. Wall Street Zen cut shares of Intelligent Bio Solutions from a “hold” rating to a “sell” rating in a report on Sunday, October 19th. Weiss Ratings restated a “sell (e+)” rating on shares of Intelligent Bio Solutions in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

Intelligent Bio Solutions Company Profile

Intelligent Bio Solutions Inc, a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners. It offers saliva glucose biosensor for diabetes management that measures glucose in saliva. The company also provides intelligent fingerprinting drug screening system, a revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields; and biosensor platform for biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities.